Who founded TauC3 Biologics?

TauC3 Biologics was founded by Daniel G. Chain in 2019.

Who are TauC3 Biologics's investors?

TauC3 Biologics's investors include Vedanta Capital.

How much funding has TauC3 Biologics raised?

TauC3 Biologics has disclosed $868.2K raised across 4 of its 5 known rounds.

Where is TauC3 Biologics headquartered?

TauC3 Biologics is headquartered in London.

TauC3 Biologics

London · Founded 2019 · Incorporated in United Kingdom · 1 known investors

Find your way into TauC3 Biologics

349 people in our graph share verified history with the TauC3 Biologics team — schools, employers, funds. One of them is your warm intro.

Cathy Friedmanunlockedknows Scott Pollack · together at Harvard University (overlapped)

×9knows the team · via University of California, Berkeley

×2knows the team · via Harvard University

TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.

Biotech Deep Tech Healthtech

Founders & leadership

TauC3 Biologics was founded in 2019 by Daniel G. Chain.

Daniel G. Chain inPresident and Chief Executive OfficerDaniel G. Chain is a neuroscientist and President and CEO of TauC3 Biologics, a biotechnology company developing therapies for neurodegenerative diseases including tau-related and Alzheimer's drug discovery. His expertise spans drug discovery and development as well as intellectual property licensing.

Scott Pollack inScientific/Platform LeaderScott Pollack is a drug discovery scientist with experience in the pharmaceutical and CRO industries, specializing in biophysical and enzymology-based approaches. He leads platform development at TauC3 Biologics, a biotechnology company focused on tau-related and Alzheimer's disease therapies.

Peter McGowanCFO

Shafique ViraniNamed on SEC filing

John GogolNamed on SEC filing

Bia GoncalvesDirector of Scientific Communications

Board

Parag Saxena inBoard directorCo-Founder & Managing Partner at Vedanta Capital

Andrew J. HeathChairman

Investors · 1

Vedanta CapitalNew York

Funding

SEC filings, press & company announcements

$868.2K disclosed across 4 of 5 rounds · 2020–2025

Undisclosed amountSeries ADec 2025
Source ↗

▶$690KraisedMar 2022 · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Parag SaxenaDirector
John GogolDirector
Daniel ChainExecutive Officer, Director
Andrew HeathDirector
Shafique ViraniDirector

Offering amount: $690K
Amount sold: $690K
First sale: Jan 2022
Incorporated: Other, United Kingdom, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$18.7KraisedDec 2020 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John GogolDirector
Shafique ViraniDirector
Andrew HeathDirector
Daniel ChainExecutive Officer, Director
Parag SaxenaDirector

Offering amount: $18.7K
Amount sold: $18.7K
First sale: Dec 2020
Incorporated: Other, United Kingdom, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$11KraisedNov 2020 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Daniel ChainExecutive Officer, Director
Andrew HeathDirector
John GogolDirector
Parag SaxenaDirector
Shafique ViraniDirector

Offering amount: $500K
Amount sold: $11K
First sale: Oct 2020
Incorporated: Other, United Kingdom, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$148.5KraisedNov 2020 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Daniel ChainExecutive Officer, Director
Andrew HeathDirector
Shafique ViraniDirector
Parag SaxenaDirector
John GogolDirector

Offering amount: $148.5K
Amount sold: $148.5K
First sale: Oct 2020
Incorporated: Other, United Kingdom, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Intechopen4 shared keywordsIntechOpen is an open access publisher of books and open science journals covering science, technology, and medicine, serving academics and researchers across interdisciplinary fields. It also operates a book series model with editorial-board-led topics and a custom manuscript submission and peer review platform.

Companies competing with TauC3 Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

TauC3 Biologics advances neurodegenerative disease treatmentlongevity.technology · Dec 2025

TauC3 Biologics prepares for Series A to advance novel neurodegenerative disease treatmentbusinessweekly.co.uk · Dec 2025

TauC3 Biologics Limited and LifeArc Announce their Selection by the Program Committee to Present at Tau2020 during the Lightning Round Poster Presentationglobenewswire.com · Feb 2020

Frequently asked questions

What does TauC3 Biologics do?: TauC3 Biologics is a biotechnology company developing therapies for neurodegenerative diseases, with a focus on tau-related and Alzheimer's disease drug discovery. It brings together drug development and neuroscience expertise to advance treatments for CNS disorders.
Who founded TauC3 Biologics?: TauC3 Biologics was founded by Daniel G. Chain in 2019.
Who are TauC3 Biologics's investors?: TauC3 Biologics's investors include Vedanta Capital.
How much funding has TauC3 Biologics raised?: TauC3 Biologics has disclosed $868.2K raised across 4 of its 5 known rounds.
Where is TauC3 Biologics headquartered?: TauC3 Biologics is headquartered in London.